Clinical effect ofQiqin decoction combined with lamivudine for the patients with hepatitis B and TCM syndrome of liver stagnation and spleen deficiency and damp heat / 国际中医中药杂志

ABSTRACT

Objective To discuss the effect ofQiqin decoction combined with lamivudine for the patients with hepatitis B and the TCM syndrome of liver stagnation and spleen deficiency and damp heat. Methods A total of 70 patients with chronic hepatitis B were divided into two groups by random number table method, 35 patients in each group. The patients in the control group were treated with lamivudine, and the patients in the observation group used lamivudine combined withQiqin decoction. The HBV-DNA was detected by fluorescence quantitative PCR, and the levels of serum ALT and AST were detected by full automatic biochemical analyzer. The TCM syndrome score of two groups were compared, and the drug resistance in the treatment process was recorded, and the clinical effect rate was evaluated.Results After treatment, the HBV-DNA negative rate of observation group was 77.1% (27/35), and the control group was 54.3% (19/35). There were statistically significant difference of the negative rate of HBV-DNA between two groups (χ2=4.136, P=0.041). The drug resistance rate of the observation group was 11.4% (4/35), and the control group was 31.4% (11/35). There were statistically significant difference of the drug resistance rate between two groups (χ2=4.297,P=0.043). After treatment, the serum ALT (29.1 ± 13.2 U/Lvs. 121.8 ± 50.2 U/L,t=5.982), the AST (28.5 ± 10.9 U/Lvs. 98.3 ± 46.1 U/L,t=8.263), the TCM syndrome scores (4.8 ± 3.1vs. 11.5 ± 7.9, t=5.982) in the observation group were significantly lower than those in the control group (P<0.01). The total effect rate of observation group was 88.6% (31/35), and the control group was 57.2% (20/35). There was significant difference between two groups (χ2=4.248,P=0.003).Conclusions The Qiqin decoction combined with lamivudine could reduce the levels of HBV-DNA, serum ALT levels and AST levels of patients with chronic hepatitis B, and improve the clinical efficacy.